[go: up one dir, main page]

NO964095L - Nye hydroksypyridinoner - Google Patents

Nye hydroksypyridinoner

Info

Publication number
NO964095L
NO964095L NO964095A NO964095A NO964095L NO 964095 L NO964095 L NO 964095L NO 964095 A NO964095 A NO 964095A NO 964095 A NO964095 A NO 964095A NO 964095 L NO964095 L NO 964095L
Authority
NO
Norway
Prior art keywords
substituted
unsubstituted
lower alkyl
mean
hydrogen
Prior art date
Application number
NO964095A
Other languages
English (en)
Other versions
NO964095D0 (no
Inventor
Paul Zbinden
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO964095D0 publication Critical patent/NO964095D0/no
Publication of NO964095L publication Critical patent/NO964095L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)

Abstract

Det er beskrevet 3-hydroksypyridln-4-oner med formel I hvor substituentene kan ha flere betydninger og R1 kan eksempelvis bety hydrogen, halogen eller substituert eller usubstituert laverealkyl eller laveralkoksy. R2 kan likeledes ha flere betydninger og blant annet bety hydrogen, substituert eller usubstituert laverealkyl eller laverealkylenhydroksy. R3 som likeledes ha ha flere betydninger kan bety hydrogen, substituert eller usubstituert laverealkyl eller karboksy, R4 kan bety hydrogen, laverealkanoyl, eller laverealkoksykarbonyl, A kan bety substituert eller usubstituert metylen eller karbonyl, B kan f.eks. bety enkeltsubstituert eller flersubstltuert eller usubstituert aryl. Forbindelsene oppviser verdifulle farmasøytiske egenskaper og er spesielt virksomme som Jernchellatorer. De kan anvendes for behandling av et Jernoverskudd i legemet av varmblodige dyr.
NO964095A 1995-09-29 1996-09-27 Nye hydroksypyridinoner NO964095L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH275995 1995-09-29

Publications (2)

Publication Number Publication Date
NO964095D0 NO964095D0 (no) 1996-09-27
NO964095L true NO964095L (no) 1997-04-01

Family

ID=4240981

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964095A NO964095L (no) 1995-09-29 1996-09-27 Nye hydroksypyridinoner

Country Status (22)

Country Link
US (1) US5688815A (no)
EP (1) EP0768302B1 (no)
JP (1) JPH09124603A (no)
KR (1) KR970015576A (no)
CN (1) CN1151399A (no)
AR (1) AR005419A1 (no)
AT (1) ATE299135T1 (no)
AU (1) AU6584596A (no)
BR (1) BR9603929A (no)
CA (1) CA2186716A1 (no)
CZ (1) CZ284896A3 (no)
DE (1) DE59611243D1 (no)
ES (1) ES2244967T3 (no)
HU (1) HUP9602681A1 (no)
IL (1) IL119316A (no)
MX (1) MX9604367A (no)
NO (1) NO964095L (no)
NZ (1) NZ299452A (no)
PT (1) PT768302E (no)
SA (1) SA96170399B1 (no)
TR (1) TR199600765A2 (no)
ZA (1) ZA968150B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
US6448273B1 (en) 1997-05-29 2002-09-10 Btg International Limited Orally active iron (III) chelators
GB9723078D0 (en) * 1997-10-31 1998-01-07 Cerebrus Ltd Chemical compounds
JPH11147377A (ja) * 1997-11-18 1999-06-02 Teijin Ltd 感熱転写リボン用二軸配向ポリエステルフィルム
US6767741B1 (en) * 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
ATE384120T1 (de) * 1999-08-27 2008-02-15 Invitrogen Corp Metallbindende verbindungen und deren verwendung in zusammensetzungen für zellkulturmedien
US6846915B2 (en) 2001-08-13 2005-01-25 The Regents Of The University Of California Hydroxypyridonate and hydroxypyrimidinone chelating agents
US6426418B1 (en) 2001-11-02 2002-07-30 Apotex, Inc. Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
JP2005516987A (ja) * 2002-02-05 2005-06-09 ブリストル−マイヤーズ　スクイブ　カンパニー Ｎ−置換された３−ヒドロキシ−４−ピリジノン化合物およびそれを含む医薬
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
NZ529657A (en) * 2003-11-20 2004-07-30 Apotex Inc Iron chelating cycloalkyl derivatives of 3-hydroxy-4-pyridinones
CA2488034C (en) * 2004-11-19 2009-10-06 Apotex Inc. Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
GB0506677D0 (en) * 2005-04-01 2005-05-11 Btg Int Ltd Iron modulators
WO2010011814A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP2012500222A (ja) * 2008-08-15 2012-01-05 バーンハム インスティテュート フォー メディカル リサーチ 金属酵素阻害剤の設計および開発のための組成物および方法
EP3617194B1 (en) * 2008-12-11 2023-11-08 VIIV Healthcare Company Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
MX2011006241A (es) 2008-12-11 2011-06-28 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
CN101906069B (zh) * 2009-06-02 2012-12-12 首都医科大学 (s)-2-取代-(3＇-乙酰基-2＇-吡啶酮-1＇-基)乙酸及其制备方法和应用
CN102712591B (zh) * 2009-07-03 2014-06-25 阿普泰克斯科技公司 3-羟基吡啶-4-酮的氟化衍生物
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
WO2012019689A2 (de) * 2010-07-27 2012-02-16 Clariant International Ltd Verwendung von hydroxypyridonen oder deren salzen zur stabilisierung von wasserstoffperoxid oder wasserstoffperoxid freisetzenden substanzen
CN105017138A (zh) * 2015-08-06 2015-11-04 中国科学技术大学 一种乙二醇化3-羟基吡啶-4-酮类化合物及其制备方法和用途
CN110790737B (zh) * 2019-11-07 2022-07-22 河南中烟工业有限责任公司 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518098A1 (de) * 1963-09-19 1969-04-10 Pfizer & Co C Verfahren zur Herstellung von Pyromekonsaeurederivaten
GB2118176B (en) * 1982-03-24 1985-12-04 Nat Res Dev Pharmaceutical compositions
GB8308054D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
US4908371A (en) * 1987-11-10 1990-03-13 Ciba-Geigy Corporation Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload
ES2047149T3 (es) * 1988-01-20 1994-02-16 Ciba Geigy Ag Procedimiento para la obtencion de compuestos complejos.
EP0335745A1 (en) * 1988-03-31 1989-10-04 The Royal Free Hospital School Of Medicine Process for producing pyrid-4-ones
US4980371A (en) * 1988-12-21 1990-12-25 Merrell Dow Pharmaceuticals Antiretroviral furan ketones
US5112968A (en) * 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
GB9100465D0 (en) * 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
GB9209078D0 (en) * 1992-04-27 1992-06-10 Hider Robert C Pharmaceutical compositions
EP0579221A1 (en) * 1992-07-17 1994-01-19 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
GB9216506D0 (en) * 1992-08-04 1992-09-16 Rice Evans Catherine A Improvements in or relating to the treatment of sickle cell disease
GB9217099D0 (en) * 1992-08-12 1992-09-23 British Tech Group Pharmaceutical compositions
US5789426A (en) * 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation

Also Published As

Publication number Publication date
TR199600765A2 (tr) 1997-05-21
HUP9602681A1 (en) 1997-09-29
ATE299135T1 (de) 2005-07-15
AU6584596A (en) 1997-04-10
BR9603929A (pt) 1998-06-09
US5688815A (en) 1997-11-18
SA96170399B1 (ar) 2007-01-20
DE59611243D1 (de) 2005-08-11
EP0768302A3 (de) 1998-02-25
NZ299452A (en) 1998-06-26
IL119316A0 (en) 1996-12-05
HU9602681D0 (en) 1996-11-28
ES2244967T3 (es) 2005-12-16
CA2186716A1 (en) 1997-03-30
JPH09124603A (ja) 1997-05-13
MX9604367A (es) 1997-10-31
EP0768302A2 (de) 1997-04-16
EP0768302B1 (de) 2005-07-06
NO964095D0 (no) 1996-09-27
KR970015576A (ko) 1997-04-28
CZ284896A3 (en) 1997-04-16
ZA968150B (en) 1997-04-01
CN1151399A (zh) 1997-06-11
IL119316A (en) 2000-08-13
PT768302E (pt) 2005-11-30
AR005419A1 (es) 1999-06-23

Similar Documents

Publication Publication Date Title
NO964095L (no) Nye hydroksypyridinoner
BG104598A (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
BG92804A (bg) 4-бензоилизоксазолови производни
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
GB2248616B (en) Piperazine derivatives
ES2077071T3 (es) Derivados de quinolin-3-carboxamida.
EP0974584A4 (en) COMPOUNDS WITH CONDENSED RINGS, THEIR PRODUCTION PROCESS AND THEIR USE
BG104575A (en) Matrix metalloprotease inhibitors
BG105249A (en) Fkbp inhibitors
DE59108566D1 (de) Heteroarylmethylbenzole-Aromatasehemmer
DE69815380D1 (de) N,n'-bis (sulfonyl) hydrazine die als antineoplastische mittel nützlich sind
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
MY115907A (en) Carbostyril derivatives for inhibiting skin erythema and/or skin pigmentation
NO984547L (no) Nye oksazolidinderivater, fremgangsmÕte for deres fremstilling, samt legemidler inneholdende disse forbindelser
EP1219599A4 (en) VITAMIN-D DERIVATIVES WITH SUBSTITUENTS IN THE 2-ALPHA POSITION
BG105329A (en) N-substituted azabicycloheptane derivatives, production and use thereof
ATE53839T1 (de) 2,3-dihydro-3-phenyl-benzofuran-2-onacetamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
SI1286965T1 (en) Piperidine compounds and process for providing such